• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Perrigo Announces Good Start® and Dr. Browns® Brand Partnership and Launch of Infant Formula Portfolio

    9/26/24 8:30:00 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRGO alert in real time by email

    DUBLIN, Sept. 26, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of Consumer Self-Care Products, today announced a new brand partnership: Good Start®1 and Dr. Brown's®2 infant formula solutions. Good Start®, a trusted infant formula brand for over 50 years, and Dr. Brown's®, makers of the No. 1 pediatrician-recommended baby bottle in the U.S.3, share a long-time mission of creating confident feeding experiences for families.

    Perrigo Announces Good Start® and Dr. Browns® Brand Partnership and Launch of Infant Formula Portfolio

    The new Good Start® | Dr. Brown's™ portfolio will offer the same trusted infant formula products as the existing Soothe Pro™ and Gentle Pro™, now with refreshed packaging to celebrate the launch of the new partnership. Good Start® | Dr. Brown's™ infant formulas offer complete nutrition specially formulated for tolerance concerns.

    Perrigo Executive Vice President and President of Consumer Self-Care Americas, Triona Schmelter commented, "We are delighted to announce this branded infant formula partnership with the exceptional team at Dr. Brown's®. Formula tolerance issues are the top reason for parents and caregivers to switch formulas 4, and bringing these two trusted infant brands together helps families confidently navigate their baby's formula-feeding journey. This new and innovative Good Start® and Dr. Brown's® partnership epitomizes Perrigo's blended-branded strategy dedicated to consumer led innovation."

    "For 25 years, Dr. Brown's® has made innovative feeding products that are trusted by parents and caretakers throughout the world to promote good health and optimal nutrition for babies and toddlers," said Scott Rhodes, Chief Operating Officer at Dr. Brown's®. "Now, by partnering with Good Start ®, we're thrilled to add another offering families can choose to include as part of their feeding journey." 

    The Good Start® | Dr. Brown's™ infant formula line includes:

    • Soothe Pro™ infant formula: Formulated with probiotic L. reuteri and helps reduce fussiness with the first bottle.5 It provides complete nutrition for babies experiencing gas, fussiness and spit-ups.
    • Gentle Pro™ infant formula: Provides complete nutrition and promotes easy digestion and softer stools.6 Gentle Pro™ includes the probiotic B. lactis, a gut-friendly probiotic like the ones found in breast milk.
    • Soy-ease Pro™ infant formula: Milk and lactose-free, made with 100% plant-based proteins. Provides complete nutrition for babies with fussiness and gas due to milk or lactose sensitivity.

    Good Start® and Dr. Brown's® are dedicated to supporting parents, caregivers and the medical community by supporting optimal nutrition solutions.

    For more information about Good Start® | Dr. Brown's™ formulas, please visit www.goodstartbaby.com. The formulas are now available in major retailers including Walmart, Amazon, Kroger and others.

    1GOOD START is a registered trademark used under license from Société des Produits Nestlé S.A.

    2Dr. Brown's is a trademark used under license from the Dr. Brown's Company

    3 IQVIA Health ProVoice Survey 2023

    4 Infant formula category brand tracking 2023, August 2023, Ravel.

    5Study results among parents of fussy infants. Czerkies L, et al. Int J Pediatr. 2018:4676758

    6Compared to intact protein formulas. Czerkies L, et al. Int J Pediatr. 2018:4676758

    About Good Start® | Dr. Brown's™ Infant Formula Solutions

    Good Start® | Dr. Brown's™ infant formula provides parents with high-quality, trusted infant formulas to create confident feeding experiences. Understanding how stressful it can be when a baby suffers from fussiness, spit-up, gas and more, Good Start® | Dr. Brown's™ infant formula solutions aim to help parents get back to the good parts of parenting with tolerance-focused solutions. Good Start® | Dr. Brown's™ Gentle Pro™ and Soothe Pro™ infant formulas are unique with gut-friendly probiotics, 100% whey proteins, free from casein curdling and made using an advanced two-step hydrolysis process, which breaks down intact proteins to make them easier to digest. For more information, visit www.goodstartbaby.com.

    About Dr. Brown's Company

    Dr. Brown's® is dedicated to providing well-designed, healthful feeding products for babies. The Dr. Brown's® lines of baby bottles, breastfeeding products, pacifiers, teethers, training cups, solid feeding and baby care products are regarded for their technology and function. Dr. Brown's® bottles have won 17 consecutive Parents/American Baby awards. The Dr. Brown's® Anti-Colic Options+™ bottles earned "Best Glass Bottle" in the 2024 Parents Magazine Best for Baby Awards, and Dr. Brown's® as a brand won "Best Bottle Brand" in the 2024 What to Expect Feeding Awards. Dr. Brown's® products are available at baby specialty and online retailers worldwide. For more information, visit drbrownsbaby.com.  

    About Perrigo 

    Perrigo Company plc (NYSE:PRGO) is a leading provider of Consumer Self-Care Products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. Visit Perrigo online at www.perrigo.com.

    Perrigo Forward-Looking Statements

    Certain statements in this press release are "forward-looking statements." These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. The Company bases these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control, including those caused or exacerbated by armed conflict, trade and other economic sanctions and/or disease; general economic, credit, and market conditions; customer acceptance of new products; competition from other industry participants; pricing pressures from customers and consumers; ongoing or future government investigations and regulatory initiatives; uncertainty regarding the Company's ability to obtain and maintain its regulatory approvals; potential costs and reputational impact of product recalls or sales halts; and the Company's ability to execute and achieve the desired benefits of the brand partnership described herein. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended December 31, 2023, as well as the Company's subsequent filings with the United States Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements.

    Dr. Brown's Media Contact

    Kara Hamstra, Senior Director, The Agency at Sikich, E-mail: [email protected] 

    Perrigo Media Contact

    Madeline Nance, DJE Holdings, E-mail: [email protected]

    Perrigo Investor Contact

    Bradley Joseph, Vice President, Global Investor Relations & Corporate Communications, (269) 686-3373,

    E-mail: [email protected]

    Nicholas Gallagher, Senior Manager, Global Investor Relations & Corporate Communications, (269) 686-3238,

    E-mail: [email protected]

    Perrigo Company (PRNewsfoto/Perrigo Company plc)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/perrigo-announces-good-start-and-dr-browns-brand-partnership-and-launch-of-infant-formula-portfolio-302259885.html

    SOURCE Perrigo Company plc

    Get the next $PRGO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PRGO

    DatePrice TargetRatingAnalyst
    11/6/2025$20.00Overweight → Neutral
    Analyst
    1/14/2025Buy → Hold
    Argus
    1/6/2025$34.00 → $27.00Overweight → Neutral
    Piper Sandler
    9/24/2024$50.00 → $30.00Hold
    Jefferies
    11/17/2023$37.00Overweight
    Piper Sandler
    3/7/2023$49.00Buy
    Canaccord Genuity
    9/14/2022$46.00Hold → Buy
    Argus
    9/6/2022$48.00 → $54.00Equal Weight → Overweight
    Wells Fargo
    More analyst ratings

    $PRGO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Willis Robert

    4 - PERRIGO Co plc (0001585364) (Issuer)

    4/3/26 12:12:55 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Lockwood-Taylor Patrick

    4 - PERRIGO Co plc (0001585364) (Issuer)

    4/3/26 12:00:03 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Bezerra Eduardo Guarita

    4 - PERRIGO Co plc (0001585364) (Issuer)

    4/3/26 11:50:06 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRGO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Perrigo to Present at the UBS Global Consumer and Retail Conference

    DUBLIN, Ireland, March 3, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of consumer products, today announced that President and CEO Patrick Lockwood-Taylor is scheduled to present at the UBS Global Consumer and Retail Conference, on Wednesday, March 11th at 11:00 AM EDT. Interested parties can access the webcast on the Perrigo website at http://perrigo.investorroom.com/events-webcasts.About Perrigo Perrigo Company plc is a leading pure-play consumer health company with over a century of experience in providing high-quality health and wellness s

    3/3/26 4:30:00 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Perrigo Reports Fourth Quarter and Fiscal Year 2025 Financial Results From Continuing Operations

    Delivered FY2025 Adj. EPS at the Midpoint of Updated Outlook RangeAdvanced '3-S Plan' with Perrigo Store Brand OTC and Key Brands Gaining Share1,2 in 2025, Despite Soft Category ConsumptionLaunching New Operational Enhancement Program - Expected to Deliver Pre-Tax Annualized Savings of $80 million to $100 millionTransitioning to New Reporting Segments Beginning Q1 2026, Aligned to Commercial Operating ModelIssues FY2026 'All In' Outlook; Introduces FY2026 'CORE' Outlook, which Excludes Infant Formula and Previously Announced DivestituresFourth Quarter 2025 YoY Highlights:Net Sales: $1.11 billion, -2.5% year-over-year as favorable FX +2.3% was more than offset by organic net sales -4.5% and t

    2/26/26 6:31:00 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Perrigo Announces Quarterly Dividend

    DUBLIN, Feb. 19, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of consumer products, today announced that its Board of Directors has approved a quarterly dividend of $0.29 per share, or $1.16 per share on an annualized basis. The cash dividend is payable on March 24, 2026, to shareholders of record on March 2, 2026. About Perrigo Perrigo Company plc is a leading pure-play consumer health company with over a century of experience in providing high-quality health and wellness solutions to consumers primarily in North America and Europe. As a pione

    2/19/26 9:00:00 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRGO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 13, 2023 - FDA Approves First Nonprescription Daily Oral Contraceptive

    For Immediate Release: July 13, 2023 Today, the U.S. Food and Drug Administration approved Opill (norgestrel) tablet for nonprescription use to prevent pregnancy— the first daily oral contraceptive approved for use in the U.S. without a prescription. Approval of this progestin-only oral contraceptive pill provides an option for consumers to purchase oral contraceptive medicine without a prescription at drug stor

    7/13/23 8:32:15 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRGO
    SEC Filings

    View All

    SEC Form DEFA14A filed by Perrigo Company plc

    DEFA14A - PERRIGO Co plc (0001585364) (Filer)

    4/3/26 3:25:18 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Perrigo Company plc

    SCHEDULE 13G/A - PERRIGO Co plc (0001585364) (Subject)

    3/26/26 11:55:48 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Perrigo Company plc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - PERRIGO Co plc (0001585364) (Filer)

    3/23/26 4:18:48 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRGO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Perrigo downgraded by Analyst with a new price target

    Analyst downgraded Perrigo from Overweight to Neutral and set a new price target of $20.00

    11/6/25 8:47:26 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Perrigo downgraded by Argus

    Argus downgraded Perrigo from Buy to Hold

    1/14/25 8:38:48 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Perrigo downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Perrigo from Overweight to Neutral and set a new price target of $27.00 from $34.00 previously

    1/6/25 8:24:36 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRGO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Parker Geoffrey M. bought $106,350 worth of Ordinary Shares (7,500 units at $14.18) (SEC Form 4)

    4 - PERRIGO Co plc (0001585364) (Issuer)

    11/14/25 10:45:37 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP and CSO Lennox Abigail bought $28,125 worth of Ordinary Shares (1,255 units at $22.41) (SEC Form 4)

    4 - PERRIGO Co plc (0001585364) (Issuer)

    9/10/25 4:19:48 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, General Counsel & Sec. Atkinson Charles bought $23,200 worth of Ordinary Shares (1,000 units at $23.20) (SEC Form 4)

    4 - PERRIGO Co plc (0001585364) (Issuer)

    9/9/25 3:47:36 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRGO
    Leadership Updates

    Live Leadership Updates

    View All

    CRH, Carvana and Comfort Systems USA Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Dec. 5, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 22, to coincide with the quarterly rebalance. The changes ensure that each index is more representative of its market capitalization range. The companies being removed from the S&P SmallCap 600 are no longer representative of the small-cap market space.  Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector Dec 22, 2025  S&P 500 Addition CRH CRH Mat

    12/5/25 5:49:00 PM ET
    $ASIX
    $BAH
    $BWA
    Major Chemicals
    Industrials
    Professional Services
    Consumer Discretionary

    Perrigo Announces Global Operations and Supply Chain Leadership Transition

    Ron Janish, EVP Global Operations and Supply Chain, to Retire Industry Veteran, Matt Winterman, Appointed EVP Product Supply, Operations Strategy & Transformation Officer DUBLIN, June 4, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of Consumer Self-Care Products, today announced the appointment of Matt Winterman as Executive Vice President, Product Supply, Operations Strategy and Transformation Officer, effective June 23, 2025. Mr. Winterman succeeds Ron Janish, who will retire from the Company on September 30, 2025, following a distinguished career at Perrigo spanning more than two decades. Both executives will closely work together to ensure a smooth tran

    6/4/25 8:30:00 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Perrigo Expands its Scientific Office; Appoints Abbie Lennox as Executive Vice President and Chief Scientific Officer

    Expanded Scientific Office Unifies Scientific-Focused Teams, Facilitating Seamless Collaboration Across Product Portfolio Lennox Most Recently Led Regulatory, Medical Affairs, Safety and Quality Teams, Plus Drove Product Innovation, at Bayer Consumer Health Previous Chief Scientific Officer, Alison Ives, to Lead Newly Formed Disruptive Growth Team DUBLIN, Jan. 6, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of Consumer Self-Care Products, today announced the expansion of its Chief Scientific Office by uniting and integrating all global quality, pharmacovigilance, patient safety, regulatory affairs and innovation teams, enhancing organizational agility and s

    1/6/25 8:00:00 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRGO
    Financials

    Live finance-specific insights

    View All

    Perrigo Reports Fourth Quarter and Fiscal Year 2025 Financial Results From Continuing Operations

    Delivered FY2025 Adj. EPS at the Midpoint of Updated Outlook RangeAdvanced '3-S Plan' with Perrigo Store Brand OTC and Key Brands Gaining Share1,2 in 2025, Despite Soft Category ConsumptionLaunching New Operational Enhancement Program - Expected to Deliver Pre-Tax Annualized Savings of $80 million to $100 millionTransitioning to New Reporting Segments Beginning Q1 2026, Aligned to Commercial Operating ModelIssues FY2026 'All In' Outlook; Introduces FY2026 'CORE' Outlook, which Excludes Infant Formula and Previously Announced DivestituresFourth Quarter 2025 YoY Highlights:Net Sales: $1.11 billion, -2.5% year-over-year as favorable FX +2.3% was more than offset by organic net sales -4.5% and t

    2/26/26 6:31:00 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Perrigo Announces Quarterly Dividend

    DUBLIN, Feb. 19, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of consumer products, today announced that its Board of Directors has approved a quarterly dividend of $0.29 per share, or $1.16 per share on an annualized basis. The cash dividend is payable on March 24, 2026, to shareholders of record on March 2, 2026. About Perrigo Perrigo Company plc is a leading pure-play consumer health company with over a century of experience in providing high-quality health and wellness solutions to consumers primarily in North America and Europe. As a pione

    2/19/26 9:00:00 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Perrigo to Release Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026

    DUBLIN, Feb. 13, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading provider of consumer health products, today announced that it plans to issue its fourth quarter and fiscal year 2025 financial results on Thursday, February 26th, 2026, and host a conference call beginning at 8:30 A.M. (EST). The earnings conference call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 800-836-8184, International 646-357-8785, and reference ID # 52719.

    2/13/26 8:30:00 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRGO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Perrigo Company plc

    SC 13G - PERRIGO Co plc (0001585364) (Subject)

    10/31/24 11:55:03 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Perrigo Company plc

    SC 13G - PERRIGO Co plc (0001585364) (Subject)

    2/13/24 1:05:29 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Perrigo Company plc (Amendment)

    SC 13G/A - PERRIGO Co plc (0001585364) (Subject)

    1/24/24 2:27:16 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care